slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
191,161-191,220 of 319,975
21
Roivant Sciences | Investor Presentation Deck | 21 slidesRoivant Sciences | Investor Presentation Deck | 21 slides · Immunovant
Pitch deck Investor relations 1 hit
01
Includes exhibit number and presenter credentials.SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
02
Page number 2 in the top right corner.SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
03
SAB Biotherapeutics | Results Presentation Deck | 12 slidesSAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
04
The slide uses a process flow diagram to explain a proprietary biotechnology manufacturing method.SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
05
The table uses color coding to distinguish between vaccine strains (green) and non-vaccine strains (blue).SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
06
Details the study sponsorship, location, participant demographics, dosing, and timeline.SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
07
Clinical trial design disclosure.SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
08
Standard CONSORT-style participant flow diagram.SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
09
The slide presents two line charts comparing treatment and placebo groups over time relative to viral challenge.SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
10
The chart shows a clear separation between the treatment and placebo groups, indicating faster viral clearance in the treatment arm.SAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
11
SAB Biotherapeutics | Results Presentation Deck | 12 slidesSAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
12
SAB Biotherapeutics | Results Presentation Deck | 12 slidesSAB Biotherapeutics | Results Presentation Deck | 12 slides · SAB Biotherapeutics
Regulatory filing Investor relations 1 hit
01
Salvatore Ferragamo | Results Presentation Deck | 13 slidesSalvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · Attention1 hit
02
Salvatore Ferragamo | Results Presentation Deck | 13 slidesSalvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations 1 hit
03
Salvatore Ferragamo | Results Presentation Deck | 13 slidesSalvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
04
Salvatore Ferragamo | Results Presentation Deck | 13 slidesSalvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
05
The table highlights 2022 data with a light blue background column. Includes a disclaimer about restated 2021 data and exclusion of cash flow hedge effects.Salvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
06
Includes a disclaimer about restated 2021 data and exclusion of cash flow hedge effects.Salvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
07
Includes a highlight box around the 2022 column. Data is in Euro MM.Salvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
08
The table compares 2022 and 2021 June YTD figures with percentage changes.Salvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
09
The table includes a breakdown of Net Invested Capital and Financial Sources, with a secondary section calculating Adjusted Net Debt.Salvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations 1 hit
10
The table includes a footnote regarding the exclusion of cash flow hedge effects for performance analysis.Salvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations 1 hit
11
Includes a disclaimer regarding the exclusion of cash flow hedge effects and restated 2021 data.Salvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations 1 hit
12
Includes a footnote regarding the exclusion of cash flow hedge effects and restatement of 2021 data.Salvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations 1 hit
13
Salvatore Ferragamo | Results Presentation Deck | 13 slidesSalvatore Ferragamo | Results Presentation Deck | 13 slides · Salvatore Ferragamo
Conference presentation Investor relations Beat · Action1 hit
01
Signature Bank | Results Presentation Deck | 3 slidesSignature Bank | Results Presentation Deck | 3 slides · Signature Bank
Conference presentation Investor relations Beat · Attention1 hit
02
The slide highlights the impact of crypto market volatility on digital asset deposits versus growth in other banking divisions.Signature Bank | Results Presentation Deck | 3 slides · Signature Bank
Conference presentation Investor relations Beat · Interest1 hit
03
Signature Bank | Results Presentation Deck | 3 slidesSignature Bank | Results Presentation Deck | 3 slides · Signature Bank
Conference presentation Investor relations 1 hit
01
Skillsoft | Results Presentation Deck | 14 slidesSkillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations Beat · Attention1 hit
02
Skillsoft | Results Presentation Deck | 14 slidesSkillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations 1 hit
03
Skillsoft | Results Presentation Deck | 14 slidesSkillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations 1 hit
04
Skillsoft | Results Presentation Deck | 14 slidesSkillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations Beat · Interest1 hit
05
The table uses a waterfall-style logic to explain the variance between previous and updated outlooks.Skillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations Beat · What Could BeLoop · Cost Of Inaction1 hit
06
Includes notes on fiscal year end, product level view, and Codecademy inclusion.Skillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations Beat · What Is1 hit
07
Proforma values include Codecademy starting April 5th of each year. Fiscal years end January 31.Skillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations Beat · What Is1 hit
08
The slide provides a clear comparison of financial metrics pre- and post-divestiture.Skillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations 1 hit
09
Skillsoft | Results Presentation Deck | 14 slidesSkillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations 1 hit
10
The table uses Treasury Stock Method (TSM) for calculations.Skillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations 1 hit
11
Includes reconciliation of operating loss, adjusted net income, and adjusted EBITDA.Skillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations 1 hit
12
The table reconciles Skillsoft Corp. GAAP results to a combined view including revenue adjustments.Skillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations 1 hit
13
Includes footnotes explaining the adjustments for Global Knowledge, Skillsoft, and Codecademy.Skillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations 1 hit
14
Includes footnotes explaining GAAP results of Skillsoft, non-GAAP revenue adjustments, and Codecademy proforma adjustments.Skillsoft | Results Presentation Deck | 14 slides · Skillsoft
Conference presentation Investor relations 1 hit
01
The slide features a high-quality photograph of an aircraft hangar facility.SkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations 1 hit
02
SkyHarbour | Investor Presentation Deck | 8 slidesSkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations 1 hit
03
SkyHarbour | Investor Presentation Deck | 8 slidesSkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations Beat · Problem1 hit
04
The slide outlines a financial challenge (funding gap) and specific operational strategies to address it.SkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide details a specific bond indenture modification strategy to improve credit metrics.SkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
06
SkyHarbour | Investor Presentation Deck | 8 slidesSkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The slide uses red dots to indicate achievement status for various line items.SkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
08
SkyHarbour | Investor Presentation Deck | 8 slidesSkyHarbour | Investor Presentation Deck | 8 slides · SkyHarbour
Pitch deck Investor relations Beat · Action1 hit
01
Exhibit 99.2 identifier present.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · Problem1 hit
02
TCR2 Therapeutics | Results Presentation Deck | 34 slidesTCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · Problem1 hit
03
TCR2 Therapeutics | Results Presentation Deck | 34 slidesTCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · Problem1 hit
04
Includes a list of abbreviations at the bottom.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · Problem1 hit
05
The slide uses a visual comparison framework to position TRuC-T cells as a superior technological evolution.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
06
The slide uses a 2x2 layout to present four distinct experimental results supporting the superiority of TRuC technology.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
07
The slide uses a comparative structure to frame gavo-cel as a superior therapeutic option compared to historical anti-mesothelin CAR-T approaches.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
08
The chart is a classic waterfall plot used in oncology clinical trials to demonstrate efficacy.TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
09
Waterfall plot showing individual patient responses; includes specific clinical trial metrics (ORR, PFS, OS).TCR2 Therapeutics | Results Presentation Deck | 34 slides · TCR2 Therapeutics
Regulatory filing Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit